Critical need for clarity in polymyxin B dosing

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 5, 2017, Pages

  Onufrak, Nikolas J ^a   Rao, Gauri G ^a   Forrest, Alan ^a   Pogue, Jason M ^b   Scheetz, Marc H ^c,d   Nation, Roger L ^e   Li, Jian ^e   Kaye, Keith S ^f  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MIDWESTERN UNIVERSITY   (United States)

^d NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^e MONASH UNIVERSITY   (Australia)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Pharmacodynamics; Pharmacokinetics; Polymyxin B

Indexed keywords

POLYMYXIN B; ANTIINFECTIVE AGENT;

CRITICALLY ILL PATIENT; DOSE RESPONSE; DRUG EXCRETION; DRUG EXPOSURE; DRUG UTILIZATION; GRAM NEGATIVE INFECTION; HUMAN; LETTER; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; POLYMYXIN B;

EID: 85018184132     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00208-17     Document Type: Letter

References (12)

1. Thamlikitkul V, Dubrovskaya Y, Manchandani P, Ngamprasertchai T, Boonyasiri A, Babic JT, Tam VH. 2017. Dosing and pharmacokinetics of polymyxin B in renal insufficiency. Antimicrob Agents Chemother 61: e01337-16. https://doi.org/10.1128/AAC.01337-16.
2. Zavascki AP, Goldani LZ, Cao G, Superti SV, Lutz L, Barth AL, Ramos F, Boniatti MM, Nation RL, Li J. 2008. Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clin Infect Dis 47:1298-1304. https://doi.org/10.1086/592577.
3. Sandri AM, Landersdorfer CB, Jacob J, Boniatti MM, Dalarose MG, Falci DR, Behle TF, Bordinhao RC, Wang J, Forrest A, Nation RL, Li J, Zavascki AP. 2013. Population pharmacokinetics of intravenous polymyxin B in critically Ill patients: implications for selection of dosage regimens. Clin Infect Dis 57:524-531. https://doi.org/10.1093/cid/cit334.
4. Bedford Laboratories. 2011. Polymyxin B for injection. USP package insert. Bedford Laboratories, Bedford, OH.
5. Nelson BC, Eiras DP, Gomez-Simmonds A, Loo AS, Satlin MJ, Jenkins SG, Whittier S, Calfee DP, Furuya Y, Kubin CJ. 2015. Clinical outcomes associated with polymyxin B dose in patients with bloodstream infections due to carbapenem-resistant Gram-negative rods. Antimicrob Agents Chemother 59:7000-7006. https://doi.org/10.1128/AAC.00844-15.
6. Rigatto MH, Behle TF, Falci DR, Freitas T, Lopes NT, Nunes M, Costa LW, Zavascki AP. 2015. Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study. J Antimicrob Chemother 70:1552-1557. https://doi.org/10.1093/jac/dku561.
7. Kwa ALH, Lim TP, Low JGH, Hou JG, Kurup A, Prince RA, Tam VH. 2008. Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections. Diagn Microbiol Infect Dis 60: 163-167. https://doi.org/10.1016/j.diagmicrobio.2007.08.008.
8. Kwa ALH, Abdelraouf K, Low JGH, Tam VH. 2011. Pharmacokinetics of polymyxin B in a patient with renal insufficiency: a case report. Clin Infect Dis 52:1280-1281. https://doi.org/10.1093/cid/cir137.
9. Sandri AM, Landersdorfer CB, Jacob J, Boniatti MM, Dalarose MG, Falci DR, Behle TF, Saitovitch D, Wang J, Forrest A, Nation RL, Zavascki AP, Li J. 2013. Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis. J Antimicrob Chemother 68:674-677. https://doi.org/10.1093/jac/dks437.
10. Manchandani P, Dubrovskaya Y, Gao S, Tam VH. 2016. Comparative pharmacokinetic profiling of different polymyxin B components. Antimicrob Agents Chemother 60:6980-6982. https://doi.org/10.1128/AAC.00702-16.
11. Vozeh S, Steimer J. 1985. Feedback control methods for drug dosage optimisation. Concepts, classification and clinical application. Clin Pharmacokinet 10:457-476.
12. D'Argenio DZ, Khakmahd K. 1983. Adaptive control of theophylline therapy: importance of blood sampling times. J Pharmacokinet Biopharm 11:547-559. https://doi.org/10.1007/BF01062211.